| CUE BIOPHARMA O.N. |
| USA |
| Gesundheit |
| US22978P2056 / A426PN |
| 1UC0 (Frankfurt) / CUE (NASDAQ) |
| FRA:1UC0, ETR:1UC0, 1UC0:GR, NASDAQ:CUE |
| - |
| https://www.cuebiopharma... |
|
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel class of injectable biologics. These engineered therapies are designed to selectively engage and modulate targeted T cells, mimicking nature's signals to ..
>Volltext.. |
| 201.79 Mio. EUR |
| 194.37 Mio. EUR |
| 32.55 Mio. EUR |
| -85.04 Mio. EUR |
| -141.85 Mio. EUR |
| -23.33 EUR |
| 7.61 Mio. EUR |
| 15.03 Mio. EUR |
| -43.26 Mio. EUR |
| 0.82 |
| 354.37% |
| -321.93% |
| - |
| - |
| - |
| CUE BIOPHARMA, CUE BIO |
| 15.08.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|